Dies ist eine HTML Version eines Anhanges der Informationsfreiheitsanfrage 'The Vaccines Procurement Steering Committee & the Joint Negotiation Team'.



 
 
 
 
 
From: xxxxxx.xxxxxxx@xx.xxxxxx.xx <xxxxxx.xxxxxxx@xx.xxxxxx.xx> 
Sent: Wednesday, September 9, 2020 9:11 AM 
To: 
 
Cc: 
@gesundheitsministerium.gv.at;
@ec.europa.eu; 
@ec.europa.eu; 
@ec.europa.eu; 
@ec.europa.eu; 
@ec.europa.eu; 
@ec.europa.eu; 
@ec.europa.eu; 
@ec.europa.eu; 
@ec.europa.eu; 
@ec.europa.eu;
@ec.europa.eu; 
@ec.europa.eu 
Subject: URGENT ‐ info about suspension  
  
Dear 
 and Dear 

  
We have been reading in the press reports about 
 

Could we have more detailed info?  
Members of the Steering Committee will be putting questions on this just ahead of finalisation of orders. 
  
Best regards, 

  
Sandra GALLINA 
Deputy Director General 


 
European Commission 
DG SANTE  
SANTE.DG1 in charge of Directions B and C 
  
  Office 
 
B-1049 Brussels/Belgium 
 
 Tel. +32 2 29
 
  Fax +32 2 29
 
xxxxxx.xxxxxxx@xx.xxxxxx.xx 
  
  
  
 
AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered 
office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. 
This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged 
information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, 
highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited 
and its affiliates may process information, personal data and monitor communications, please see our privacy notice at 
www.astrazeneca.com